Deoxynucleosides with benzimidazoles as aglycone moiety are potent anticancer agents
Mirosława Koronkiewicz1, Zdzisław Chilmonczyk1, Zygmunt Kazimerczuk2
1Department of Cell Biology, National Medicines Institute, Chełmska St. 30/34, 00-725 Warsaw, Poland.
Abstract:
Abnormally high levels of CK2 and PIM-1 serine/threonine kinases have been documented in many cases of cancer. The elevation of CK2 and PIM-1 in cells entails suppression of apoptosis and implies a protective role for the kinases against cell death. Downregulation of these enzymes by chemical methods promotes apoptosis in cells. The aim of the present study was to explore the anticancer activity of inhibitors of protein kinases CK2 and PIM-1 on neoplastic cell lines in vitro. We studied a series of deoxynucleosides with various tetrahalobenzimidazoles as aglycone moiety. Cytotoxicity, induction of apoptosis by the tested inhibitors, mitochondrial membrane potential, activity of caspases, changes in cell cycle progression, as well as a mechanism of action were determined by flow cytometry and other methods. The results indicate that the studied compounds, e.g., 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole called K164 (also termed TDB), showed diverse cytotoxicity and proapoptotic efficacy in cell lines. Our results showed that the tested compounds are potential anticancer agents for targeted therapy, particularly in the treatment of myeloid leukaemia and androgen-responsive prostate cancer.
Insights
New deoxynucleoside compounds targeting CK2 and PIM-1 kinases show promise as anticancer agents. These inhibitors effectively induce apoptosis in cancer cells, offering potential for targeted therapy in myeloid leukemia and prostate cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Elevated levels of CK2 and PIM-1 serine/threonine kinases are linked to cancer development.
- These kinases suppress apoptosis, protecting cancer cells from death.
- Inhibiting these kinases can promote cancer cell apoptosis.
Purpose of the Study:
- To evaluate the in vitro anticancer activity of novel protein kinase inhibitors.
- To explore the efficacy of deoxynucleosides with tetrahalobenzimidazole aglycones against neoplastic cells.
Main Methods:
- Synthesis and testing of deoxynucleoside derivatives.
- Flow cytometry to assess cytotoxicity, apoptosis induction, and cell cycle.
- Measurement of mitochondrial membrane potential and caspase activity.
Main Results:
- Compounds, including K164 (TDB), demonstrated varied cytotoxicity and proapoptotic effects.
- The tested inhibitors effectively induced apoptosis in cancer cell lines.
- Mechanism of action studies provided insights into their anticancer properties.
Conclusions:
- The studied deoxynucleoside derivatives are potential anticancer agents.
- These compounds show particular promise for targeted therapy in myeloid leukemia and prostate cancer.
- Further research is warranted to explore their therapeutic potential.
More Related Videos
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs that Destabilize Microtubules
Inhibition of Cdk Activity
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
